TherapeuticsMD

Q3 2025 Q2 2025 Q1 2025 Q4 2024 +6.09%Q3 2024 -1.32%Q2 2024 -1.16%Q1 2024 +2.46%Q4 2023 +1.31%Q3 2023 +17.12%Q2 2023 -3.03%Q1 2023 +0.23%Q4 2022 +0.56%Q3 2022 -15.04%Q2 2022 +4.13%Q1 2022 -12.05%Q4 2021 -27.50%Q3 2021 -12.50%Q2 2021 -4.08%Q1 2021 -14.84%Q4 2020 +0.69%Q3 2020 +10.66%Q2 2020 -18.54%Q1 2020 -5.76%Q4 2019 -14.17%Q3 2019 +4.06%Q2 2019 +17.71%Q1 2019 -12.84%Q4 2018 -1.10%Q3 2018 +5.97%Q2 2018 -14.14%Q1 2018 +2.21%Q4 2017 -8.42%Q3 2017 +27.75%Q2 2017 -6.64%Q1 2017 -6.39%Q4 2016 +3.00%Q3 2016 0.00%Q2 2016 +0.78%Q1 2016 -5.83%Q4 2015 +2.17%Q3 2015 +2.16%Q2 2015 -9.24%Q1 2015 -11.57%Q4 2014 +0.38%Q3 2014 -15.33%Q2 2014 +10.67%Q1 2014 -8.98%Q4 2013 +2.77%Q3 2013 -10.05%Q2 2013 -5.36%Q1 2013 +0.36%Q4 2012 -1.80%Q3 2012 -8.70%Q2 2012 +1.49%Q1 2012 -1.96%Q4 2011 -3.61%Q3 2011 0.00%Q2 2011 0.00%Q1 2011 +200.00%Q4 2010 -25.00%Q3 2010 0.00%Q2 2010 0.00%Q1 2010 0.00%

Mar 10, 2022

•

Dec 31, 2021

TherapeuticsMD Q4 2021 Earnings Report

Reported financial results for the fourth quarter ended December 31, 2021.

Key Takeaways

TherapeuticsMD announced its Q4 2021 financial results, highlighting a definitive agreement to divest the vitaCare business unit and amended credit terms with Sixth Street. Demand for ANNOVERA continues to grow, and the company is focused on ensuring ample supply and access.

Reached definitive agreement to fully divest vitaCare business unit.

Amended credit terms with Sixth Street.

ANNOVERA net product revenue decreased to $7.8 million.

Net loss for the fourth quarter of 2021 was $43.0 million.

Total Revenue

$18.7M

Previous year: $22.6M